1845 related articles for article (PubMed ID: 22901886)
21. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
22. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
24. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
[TBL] [Abstract][Full Text] [Related]
25. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
[No Abstract] [Full Text] [Related]
26. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
27. Mepolizumab: A Review in Eosinophilic Asthma.
Deeks ED
BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
30. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
31. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
32. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
33. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
34. Mepolizumab versus placebo for asthma.
Powell C; Milan SJ; Dwan K; Bax L; Walters N
Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
36. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
38. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.
Ortega H; Li H; Suruki R; Albers F; Gordon D; Yancey S
Ann Am Thorac Soc; 2014 Sep; 11(7):1011-7. PubMed ID: 24983709
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
[TBL] [Abstract][Full Text] [Related]
40. Stopping
Moore WC; Kornmann O; Humbert M; Poirier C; Bel EH; Kaneko N; Smith SG; Martin N; Gilson MJ; Price RG; Bradford ES; Liu MC
Eur Respir J; 2022 Jan; 59(1):. PubMed ID: 34172470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]